Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection
SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment.
Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1
"Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy."
The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices.
Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025.
Visit https://www.cepheid.com/en_CA for more information.
Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https://doi.org/10.1038/s41598-023-31103-y
About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.
IVD. In Vitro Diagnostic Medical Device. May not be available in all countries
For Cepheid Media Inquiries:Darwa Petersonmedia.communications@cepheid.com
SOURCE Cepheid
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/04/c5723.html
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Omada Health IPO signals healthier market, avoids 'down-round' trend
The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first trading day on Friday at $23 a share, a 21% jump from the IPO price of $19. The IPO valued the company just above $1 billion (excluding employee options), a figure that's nearly identical to Omada's last private valuation of $1 billion set in its previous VC round. The debut is one of the first among recent IPOs that was not a so-called down-round. Many of the latest public listings, including Hinge, ServiceTitan, and Reddit, priced below their private market highs, though have faired well as public companies. For founder and CEO Sean Duffy, the successful public offering validates his decision to start a company that he believed the market desperately needed. In 2011, he dropped out of Harvard Medical School after realizing that chronic illness patients required more continuous support than the existing healthcare system delivered. Before the offering, he owned 4.1% of the company, according to Omada's offering document. Other significant shareholders included Revelation Partners (10.9%), US Venture Partners (9.9%), Andreessen Horowitz (9.6%), and FMR (9.3%). Duffy told TechCrunch that over his 14-year journey as a founder, he had many harrowing moments. "I didn't think our series A was going to come together because we were working on this commercial deal that didn't materialize, and that spooked one investor," he said. "As a young business, something tries to kill you every month," he continued. "And then as the business grows, it turns into like every quarter or six months, year, two years." One of the recent challenges for many digital health businesses is navigating the "collapse" of the market post-COVID boom. Omada steered through the turbulent times by seeking new, rising markets. It recently expanded its offerings to include diet management support for GLP-1 patients.
New York Post
2 hours ago
- New York Post
Trump orders FAA to remove supersonic flight restrictions: ‘Bold new chapter in aerospace innovation'
President Trump is boosting supersonic aviation in the United States. An executive order the commander in chief signed Friday directs the Federal Aviation Administration to repeal a 1973 rule prohibiting overland supersonic flight, establish new noise standards for aircraft and remove other regulations that get in the way of the development of high-speed planes. 'The United States stands at the threshold of a bold new chapter in aerospace innovation,' the president wrote in the order. Advertisement 'For more than 50 years, outdated and overly restrictive regulations have grounded the promise of supersonic flight over land, stifling American ingenuity, weakening our global competitiveness, and ceding leadership to foreign adversaries.' 3 'President Trump is Making Aviation Great Again,' the White House said of the his executive order. AFP via Getty Images Trump argued that advances in engineering and technology have now made supersonic air travel 'not just possible, but safe, sustainable, and commercially viable.' Advertisement 'This order begins a historic national effort to reestablish the United States as the undisputed leader in high-speed aviation,' the president declared. 'By updating obsolete standards and embracing the technologies of today and tomorrow, we will empower our engineers, entrepreneurs, and visionaries to deliver the next generation of air travel, which will be faster, quieter, safer, and more efficient than ever before.' Under current FAA rules, only military aircraft – flying in specially designated areas – are allowed to break the sound barrier over land. The 1973 ban on overland supersonic flight was primarily due to the disruptive impact of the sonic booms produced when aircraft exceed the speed of sound. 3 Boom Supersonic hopes to develop a commercially viable supersonic aircraft. AP Advertisement 3 The FAA banned supersonic flights over the United States in 1973, over noise concerns. Chad Robertson – However, new technology has enabled one aircraft maker, Boom Supersonic, to develop a plane that can cruise above Mach 1 without emitting a sonic boom. 'Supersonic is back, baby!' Boom Supersonic founder and CEO Blake Scholl wrote on X, noting that in January, his company's XB-1 aircraft became the first privately developed supersonic jet to break the sound barrier. 'And today…[Trump] broke the sound barrier…permanently!' he added. Advertisement Scholl argued that the ban on supersonic flight has 'crippled progress' in aviation for half a century, but with Trump's order in place, 'The supersonic race is on and a new era of commercial flight can begin.' 'By removing decades-old regulatory barriers and promoting cutting-edge supersonic technology, President Trump is Making Aviation Great Again,' the White House said in a statement.
Yahoo
3 hours ago
- Yahoo
Oakland County issues alert for measles exposure site in Rochester Hills
FOX 2 - The Oakland County Health Division is notifying the public about a Rochester Hills measles exposure site involving a person from another county. The exposure site is a medical office building at 3950 S. Rochester Road at the corner of South Boulevard on Tuesday, June 3, according to a release from the Oakland County Health Division. Anyone there between 8 a.m. and 7:30 p.m. may have been exposed to measles. If you think you were exposed to measles at this location on June 3, Immune Globulin (IG) treatment is effective within six days of exposure for high-risk individuals. Those considered high-risk include women who are pregnant, unvaccinated children under age 5 and those who have a weakened immune system due to illness and disease including diabetes or HIV, malnutrition and/or medications. If you are not eligible for IG, monitor symptoms through June 24. If symptoms develop, call ahead to your health care provider. Individuals born in or before 1957 are considered immune. Measles is a highly contagious, vaccine-preventable disease that is spread by direct person-to-person contact and through the air. The Health Division recommends unvaccinated individuals ages 1 year and older receive a measles vaccination to protect themselves and those around them. Anyone who doesn't have a record of two MMR vaccines, unsure if they've have been vaccinated, or unsure if you've had measles in the past, needs to contact their health care provider. Measles can live for up to two hours in the air where an infected person coughed or sneezed. Symptoms of measles usually begin 7-14 days after exposure, but can appear up to 21 days after exposure, and may include: High fever (may spike to over 104°F Cough Runny nose Red, watery eyes (conjunctivitis) Tiny white spots on the inner cheeks, gums and roof of mouth (Koplik Spots) 2-3 days after symptoms begin. A rash that is red, raised, blotchy; usually starts on face, spreads to trunk, arms and legs 3-5 days after symptoms begin. The MMR vaccine is available through some health care providers, Oakland County Health Division offices in Southfield and Pontiac, and many pharmacies. Health Division offices are located at the following addresses: North Oakland Health Center, 1200 N. Telegraph Road, Building 34 East, Pontiac South Oakland Health Center, 27725 Greenfield Road, Southfield. Health Division clinics hours are Monday, Wednesday and Friday 8:30 a.m. – 5 p.m. Tuesday 9:30 a.m. – 6 p.m. and Thursday 7:30 a.m. – 5 p.m. Visit for more information on measles, or contact Nurse on Call, 8:30 a.m. to 5 p.m. Monday through Friday, at 800-848-5533 or noc@
